Once the subcutaneous tumor volume reached 200 mm3, a combination of the dose‐escalating PRMT5 inhibitors GSK3326595 and CPT‐11 was administered to determine the optimal therapeutic dose (Figure S4B–D, Supporting Information). The gene discussed is PRMT5; the disease is neoplasm.